Moderna Q2 Earnings: Earnings Beat, COVID-19 Inventory Write-Off, Additional Share Buyback

Moderna Inc MRNA reports a Q2 EPS of $5.24, compared to the $6.46 posted a year ago, beating the consensus estimate of $4.59.

Revenue was $4.75 billion compared to $4.34 million a year ago, beating the consensus of $4.07 billion. Sequentially sales declined almost 22% from $6.1 billion. Product sales were $4.5 billion, +8% Y/Y, primarily driven by a higher average selling price due to the customer mix.

The company incurred $499 million for inventory write-downs related to the COVID-19 vaccine's expiry. The charge includes a loss on firm purchase commitments of $184 million and an expense for an unutilized external manufacturing capacity of $131 million. 

Operating income reached $2.45 billion, down from $3.06 billion a year ago. Moderna held cash, cash equivalents, and investments of $18.1 billion.

Buyback: Moderna has authorized an additional share repurchase program for $3 billion. The $3 billion repurchase program announced in February is continuing and currently has approximately $1 billion outstanding.

Outlook: Moderna reiterates 2022 Advanced Purchase Agreements of approximately $21 billion, including the recently announced agreement with the U.S. government for 70 million doses.

Price Action: MRNA shares are up 4.33% at $167.77 during the premarket session on the last check Wednesday.

Photo by mufidpwt via Pixaby

Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CarePre-Market OutlookMoversTrading IdeasGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!